Self-Reported Initial Management of Childhood Idiopathic Thrombocytopenic Purpura: Results of a Survey of Members of the American Society of Pediatric Hematology/Oncology, 2001
- 1 February 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 25 (2) , 130-133
- https://doi.org/10.1097/00043426-200302000-00009
Abstract
The purpose of this study was to update physicians' self-reported initial management practices for childhood idiopathic thrombocytopenic purpura (ITP) from an initial survey in 1997. A questionnaire was sent by e-mail in October 2001 to 753 members of the American Society of Pediatric Hematology/Oncology (ASPH/O). The questionnaire had 14 questions, based on the clinical presentation of a 5-year-old boy with ITP, a platelet count of 7,000/μL, scattered petechiae, and no mucous membrane bleeding. Two hundred eighteen (29%) surveys were returned. In response to questions regarding initial treatment, 33% of physicians said they would always administer drug therapy, 38% usually, 15% sometimes, and 14% rarely/never. When asked which agent would be used if drug treatment were prescribed, 45% reported anti-D, 33% IVIG, 20% prednisone, and 2% other regimens. Only 34% of physicians would always or usually hospitalize such a patient. Hospitalization was more likely if a physician responded that he or she would always or usually use drug therapy. Physicians who saw more ITP patients were more likely to self-report sometimes or rarely/never prescribing drug therapy. Self-reported initial management of ITP by ASPH/O members in 2001 is similar to 1997 regarding the percentage of pediatric hematologists who would not use drug therapy. Among physicians who would use drug treatment, there was an increased use of anti-D and decreased use of IVIG and prednisone. This information provides the basis for designing a randomized clinical trial to compare the effect of different management strategies on the outcomes of bleeding symptoms, side effects of therapy, costs, and quality of life.Keywords
This publication has 9 references indexed in Scilit:
- The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatmentThe Journal of Pediatrics, 2000
- Initial management of immune thrombocytopenic purpura in children: Is supportive counseling without therapeutic intervention sufficient?The Journal of Pediatrics, 2000
- Idiopathic thrombocytopenic purpura: beyond consensusCurrent Opinion in Pediatrics, 2000
- Self-Reported Diagnostic and Management Strategies in Childhood Idiopathic Thrombocytopenic Purpura: Results of a Survey of Practicing Pediatric Hematology/Oncology SpecialistsJournal of Pediatric Hematology/Oncology, 2000
- Management of childhood idiopathic thrombocytopenic purpuraBritish Journal of Haematology, 1999
- Immune thrombocytopenic purpura: Why treat?The Journal of Pediatrics, 1999
- Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology [see comments]Blood, 1996
- A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpuraThe Journal of Pediatrics, 1993
- Guidelines for management of idiopathic thrombocytopenic purpura. The British Paediatric Haematology Group.Archives of Disease in Childhood, 1992